Loading organizations...
Joyo Capital Partners functions as the corporate venture capital arm of Joyo Bank, executing strategic investments in innovative startups. The firm maintains a sector-agnostic approach, yet demonstrates interest in deep technology and sustainability, as seen in its backing of companies developing advanced nuclear fusion. These investments align with the broader strategic objectives of its parent financial institution.
Established in 2021, Joyo Capital Partners was founded by Joyo Bank. This investment vehicle reflects the bank's initiative to channel capital into emerging technological ventures, fostering innovation and exploring new business opportunities beyond traditional banking. It leverages the parent bank's financial foundation and market insight.
The firm primarily backs early-stage companies and innovators seeking growth capital and strategic partnerships. Joyo Capital Partners cultivates a portfolio of high-potential enterprises, contributing to regional economic development and integrating disruptive technologies. Its long-term vision centers on driving sustainable growth and innovation within the Japanese market.
Joyo Capital Partners has 3 tracked investments across 2 companies. The latest tracked deal is $7.0M Series B in Celaid Therapeutics in October 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 7, 2025 | Celaid Therapeutics | $7.0M Series B | — | Japanese Agency For Medical Research And Development, Osaka University Venture Capital, Technoscience, Atsushi Usami |
| May 8, 2024 | Celaid Therapeutics | $4.3M Grant / Series A Extension | — | Nedo, Osaka University Venture Capital, SBI Investment, Technoscience, Atsushi Usami |
| Jan 31, 2024 | Tenchijin | $1.7M Series A | Yuki Takemori | Jalux, Skylight J SAT, Zenrin Future Partners |
